Conconi A, et al. - Since the progression of disease within two years from the start of therapy (POD24) was associated with a poor result in follicular lymphoma who received first-line systemic therapy, researchers tried to understand whether early progression after first-line treatment also affects overall survival (OS) in extranodal marginal zone B-cell lymphomas of MALT type (EMZL). Study participants included 401 EMZL patients (131 randomly assigned to chlorambucil treatment, 138 to rituximab and 132 to chlorambucil plus rituximab). According to findings, POD24 has been noted in 69 of 401 patients of the IELSG19 study. Data reported that the 10-year OS rate was 64% in the POD24 group and 85% in the reference group. Patients in the early POD group were more likely than those in the reference group to have high-risk MALT-IPI scores. The authors concluded that POD24 was linked to poorer survival and can represent a useful endpoint in future prospective clinical trials in patients with EMZL who received front-line systemic treatment.